Participated · Equity · Apr 2021

Grin's core products are the Grin App and the FDA-listed Grin Scope, which together enable patient self-scans and virtual check-ins under doctors' supervision. The platform supports continuous remote monitoring to reduce chair time and increase patient volume. Grin says it has captured millions of scans for tens of thousands of patients and is used by over 2,000 care providers globally, and that its technology delivers clinical images five times faster than prior solutions. The company runs programs accessible through Medicaid and via schools, long-term care facilities, and clinics to improve oral health equity. Grin was recognized with the 2024 Digital Health Award for Emerging Innovation in Dental Health and received a $50,000 grant from the Digital Health Hub Foundation. The announced investment is intended to support growth and expansion to streamline access to dental care. Grin offers the Grin App alongside FDA-listed Grin Scope and Grin Scope Mini devices that attach to smartphone cameras to scan and measure changes to patients' teeth. Under the supervision of partner doctors, these technologies enable virtual check-ins to remotely monitor tooth movement, gum health, and oral hygiene. The platform is intended to reduce office visits by allowing providers to transition routine patient check-ins from in-office to virtual, which can decrease chair time and increase patient volume. Grin positions itself as a 'for orthos, by orthos' solution under CEO and co-founder Adam Schulhof, DMD, and emphasizes connecting patients with real local orthodontists. The company received the 2021 AAO Ortho Innovator Award. Grin recently announced a strategic investment from the American Association of Orthodontists' Innovation & Transformation Fund. Grin is built around the Grin App and the FDA-listed Grin Scope, an intraoral adapter that enables patients to self-scan their teeth for orthodontist-ready videos. The platform connects patients to real local orthodontists for remote monitoring and virtual check-ins, which Grin says reduces chair time and increases patient volume. Founded in 2019 by Adam Schulhof DMD, Pamela Oren-Artzi, and Alon Lipnik, the company is deployed at hundreds of orthodontic practices and is being used by thousands of patients who have provided tens of thousands of self-scans across the US. Grin plans to use new funding to expand geographic reach, grow its orthodontic partner network, and implement additional platform features for an end-to-end patient care continuum. R&D will focus on enhanced teeth scanning via the Grin App and Grin Scope and features to assist doctors in treating complex teeth-straightening cases. The company announced a $10M funding round (bringing total funding to $14M) and intends to invest proceeds in technology, talent, and partner onboarding.

Participated · Series A · Dec 2020

Founded in 2001 and based in Trenton, N.J., TerraCycle US builds and scales recycling solutions for materials not typically accepted in curbside programs, covering hundreds of waste streams such as snack wrappers, coffee pods, cosmetics, pet food bags, and car seats. The company reported growing U.S. revenue 75% over four years, from $24.7 million in 2020 to $43.1 million in 2024, and generated $19.3 million in gross profit in 2024 while remaining consistently profitable. TerraCycle US has completed three strategic acquisitions since 2018 to expand operational capabilities and strengthen its market position, and it has partnered with major brands and retailers including P&G, Nestle, and Walmart. The broader TerraCycle network has collected and recycled over 8 billion items, raised $20 million for schools and nonprofits, and received numerous industry awards. The company intends to use proceeds from the Regulation A raise to fund further strategic acquisitions and disciplined growth to drive recurring revenue and durable market leadership.

Participated · Series C · Feb 2010

Navigenics offers personalized genetic testing technology that gives individuals a view into their DNA and reveals genetic predispositions for important health conditions. The company aims to help people apply these insights to improve preventive health decisions. The new capital will enable Navigenics to continue research into the impact of genomics on preventive health care and to expand its clinical offerings. Navigenics also plans to integrate personal genomics into employer-sponsored preventive health and wellness programs. The company raised approximately $18M in a Series C financing to support these efforts. Navigenics is based in Foster City, California. Navigenics is a Redwood City, Calif.–based personal-genomics company that scans millions of single-nucleotide polymorphisms (SNPs) to generate a personalized genetics analysis. The company is taking pre-orders and plans to begin delivering genetic-test results in the first quarter of the following year, initially offering roughly 20 tests. Navigenics intends to store customers' gene profiles and provide carefully limited, medically validated test results for conditions that can be treated or prevented, while supplying raw genetic data to individuals upon request. Pricing discussed in the coverage places an initial registration fee around $2,500 for a year of service, with additional years likely priced at about $250. The company has raised a second funding round that brings total financing to more than $25 million and counts Kleiner Perkins, Sequoia and Mohr Davidow among its investors, with Google reportedly investing as well. Many operational details—specific tests, final pricing, and exact data-delivery formats—were not yet available in the articles.